Sage Therapeutics transforms the practice of medicine

Priavoid: targeting neurological disorders with all-D-peptides

Cerevel Therapeutics: changing the course of disease

Gene therapy to treat a rare brain disease

Sanfilippo disease type C is a rare inherited neurodegenerative lysosomal storage disease caused by mutations in HGSNAT. University of Manchester scientists have developed a new gene therapy they hope will treat children with a rare but devastating brain disease, and plan to take it to a clinical trial in the near future. US-based biotech Phoenix Nest Inc. has signed a licensing deal with The University of Manchester, through its IP commercialisation company UMI3, to take the treatment to the next stage, which will involve a clinical trial on patients with Sanfilippo disease type C.

by
5 days ago

Implantable device for nonsurgical BPH treatment

Butterfly Medical develops an innovative, implantable device for the treatment of Benign Prostatic Hyperplasia (BPH). The Butterfly Medical device is a new generation device that offers a superior alternative to existing BPH minimally invasive treatments. The device’s design fits the specific shape of the prostate and dilates the prostate by retracting its lateral lobes, restricting the flow of urine. The device resembles a butterfly, the inspiration for the company’s name. As men age, their prostates grow, which can restrict the flow of urine and cause them to make multiple trips to the bathroom per night, according to Idan Geva, CEO of Butterfly Medical and former UC Berkeley master’s student in the Haas School of Business.

by
5 days ago

Braizon Therapeutics treats central nervous system diseases

Braizon Therapeutics, Inc., a biomed company, engages in research and development of new drugs, diagnostics, and life science research reagents for the central nervous system (lat. systematis nervosi centralis). Based on the outcomes of collaborative research by Professor Kazunori Kataoka from the Graduate School of Engineering/Medicine, the University of Tokyo and Professor Takanori Yokota from the Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, the company applied an innovative technology that provides drug delivery across the blood-brain barrier (BBB) in close combination with nano-material engineering and neuroscience expertise, respectively. In addition, Braizon Therapeutics was founded in 2015 and is based in Tokyo, Japan.

by
5 days ago

Researchers use endoscope to deliver gene therapy in animal study

Engineered 'suicide genes' may advance cell-replacement therapies for type 1 diabetes

Wren Therapeutics addresses protein misfolding diseases

Complete make-over in fight of multidrug-resistant tuberculosis

Several new medicines have been found to be more effective than traditional ones used to treat multidrug-resistant tuberculosis (lat. Phthisis) (MDR-TB), according to a new international collaborative study led by Dr. Dick Menzies, senior scientist at the Research Institute of the McGill University Health Centre (RI-MUHC) in Montreal. These findings precipitated a complete overhaul of worldwide TB treatment guidelines. Approximately 600,000 cases of MDR-TB emerge each year, claiming 240,000 lives. Diagnosis and treatment remain a major challenge with only one in four affected patients being diagnosed and even fewer being treated successfully. Present treatment practices of MDR-TB employ expensive, antiquated drugs that lead to toxic side effects such as constant nausea, hearing loss, and renal failure.

by
6 days ago

Smartphone app monitors on daily tuberculosis therapy

Johns Hopkins researchers report success with a smartphone video-based app that substitutes for a daily in-person visit by a health care worker required for tuberculosis (lat. Phthisis) treatment known as directly observed therapy or DOT. The preliminary study showed that the app may be less costly and may improve privacy concerns raised by patients compared to in-person visits. Video DOT offers an alternative that appears to be as effective as an in-person daily visit by health care workers to assure compliance with drug treatment but also empowers patients to manage their TB without added stress. Tuberculosis is one of the few diseases in the U.S. with state and federal provisions outlining recommended and sometimes required measures to ensure that patients adhere to treatment. 

by
6 days ago

Amylon Therapeutics uses an ultra-genetics approach to confront global disease

Amylon Therapeutics, a biotechnology company founded in 2017, targets central nervous system (lat. systematis nervosi centralis) disorders through an ultra-genetics approach, focusing on rare genetic disorders that can serve as a possible gateway to more frequently occurring indications. In other words, the company is focused on rare genetic disorders that have the potential to unlock therapies for patients worldwide. Amylon Therapeutics is led by founder Thomas de Vlaam, complemented by a scientific board of experienced scientists and biotech veterans. The company is based in Leiden, Zuid-Holland, The Netherlands.

by
6 days ago

Cookies help us deliver our Services. By using our website or clicking I agree, you agree to our use of cookies. Learn more about our cookie and privacy policy.

I AGREE

THE MOST ADVANCED SCIENCE SPINOFF SCOUTING SYSTEM:

100% Free of Cost For Scientists:

  • One hour of USA/EU attorney consulting
  • 24/7 support of 24 in-house professionals
  • 10 GB space for every scientist (own German Servers)
  • Syndicates with the leading professionals
  • 2,000 000 views of top spinoff are guaranteed
  • The largest DB of professional Investors - over 30.000

100% Free of Cost For Investors:

  • Investment information on 8,000+ spinoffs per year
  • All documents in one place (after NDA)
  • Testimonials from Key Opinion Leaders
  • AI-SDB hides irrelevant spinoffs - saved time up to 90% 
  • One-Click-Reports (OCRs) in own tailored design (PDF)

100% Free of Cost For Universities:

  • Professional Science Spinoff University Report (PDF)
  • No Links to Spinoff.com - Ready to Print and Share
  • Professional dossiers on over 27Tsd VC/PE/FO/ML
  • Professional dossiers on over 3Tsd MNC